343 related articles for article (PubMed ID: 26080005)
1. Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers.
Ho LJ; Luo SF; Lai JH
Biochem Pharmacol; 2015 Sep; 97(1):16-26. PubMed ID: 26080005
[TBL] [Abstract][Full Text] [Related]
2. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
Tanaka T; Narazaki M; Ogata A; Kishimoto T
Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001
[TBL] [Abstract][Full Text] [Related]
3. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapeutic implication of IL-6 blockade.
Tanaka T; Kishimoto T
Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
[TBL] [Abstract][Full Text] [Related]
5. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.
Tanaka T; Narazaki M; Kishimoto T
FEBS Lett; 2011 Dec; 585(23):3699-709. PubMed ID: 21419125
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 blockade in ocular inflammatory diseases.
Mesquida M; Leszczynska A; Llorenç V; Adán A
Clin Exp Immunol; 2014 Jun; 176(3):301-9. PubMed ID: 24528300
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6: A Masterplayer in the Cytokine Network.
Uciechowski P; Dempke WCM
Oncology; 2020; 98(3):131-137. PubMed ID: 31958792
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of the interleukin-6 receptor.
Tanaka T; Narazaki M; Kishimoto T
Annu Rev Pharmacol Toxicol; 2012; 52():199-219. PubMed ID: 21910626
[TBL] [Abstract][Full Text] [Related]
9. Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody.
Mihara M; Ohsugi Y; Kishimoto T
Biofactors; 2009; 35(1):47-51. PubMed ID: 19319845
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic uses of anti-interleukin-6 receptor antibody.
Kang S; Tanaka T; Kishimoto T
Int Immunol; 2015 Jan; 27(1):21-9. PubMed ID: 25142313
[TBL] [Abstract][Full Text] [Related]
11. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.
Nakahara H; Nishimoto N
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):373-81. PubMed ID: 17214583
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6: designing specific therapeutics for a complex cytokine.
Garbers C; Heink S; Korn T; Rose-John S
Nat Rev Drug Discov; 2018 Jun; 17(6):395-412. PubMed ID: 29725131
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6 as a key player in systemic inflammation and joint destruction.
Fonseca JE; Santos MJ; Canhão H; Choy E
Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
[TBL] [Abstract][Full Text] [Related]
14. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.
Tanaka T; Kishimoto T
Int J Biol Sci; 2012; 8(9):1227-36. PubMed ID: 23136551
[TBL] [Abstract][Full Text] [Related]
15. Humanized antihuman IL-6 receptor antibody, tocilizumab.
Nishimoto N; Kishimoto T
Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
[TBL] [Abstract][Full Text] [Related]
16. The biology and medical implications of interleukin-6.
Tanaka T; Kishimoto T
Cancer Immunol Res; 2014 Apr; 2(4):288-94. PubMed ID: 24764575
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade.
Jordan SC; Choi J; Kim I; Wu G; Toyoda M; Shin B; Vo A
Transplantation; 2017 Jan; 101(1):32-44. PubMed ID: 27547870
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities.
Kampan NC; Xiang SD; McNally OM; Stephens AN; Quinn MA; Plebanski M
Curr Med Chem; 2018; 25(36):4785-4806. PubMed ID: 28707587
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
Paul-Pletzer K
Drugs Today (Barc); 2006 Sep; 42(9):559-76. PubMed ID: 17028666
[TBL] [Abstract][Full Text] [Related]
20. Potential Application of Biological Products for the Treatment of Ocular Surface Inflammation.
Sakimoto T
Cornea; 2015 Nov; 34 Suppl 11():S153-7. PubMed ID: 26448173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
